کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3368984 1218993 2014 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab
چکیده انگلیسی

BackgroundReactivation of latent herpes viruses occurs with immunosuppression. Alemtuzumab is an antibody targeting CD52, which is expressed on all B- and T-cells. Treatment with alemtuzumab leads to profound T-cell suppression, and reactivation of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) occurs. Valganciclovir is used as an anti-CMV prophylaxis during alemtuzumab therapy.ObjectiveTo determine if EBV reactivation is decreased with valganciclovir prophylaxis.Study designPlasma EBV DNA was serially quantified by quantitative polymerase chain reaction with a World Health Organization EBV standard in patients receiving alemtuzumab therapy with valganciclovir as anti-CMV prophylaxis.ResultsTwenty-nine patients were studied. A total of 258 samples were quantified, at a median of 7 (3–25) specimens per patient. Twenty-four patients never had any quantifiable EBV DNA. Five patients (17%) developed EBV reactivation. Two patients had EBV reactivation at very low levels of about 103 IU/mL, 3–4 logs lower than those typically found in post-transplant lymphoproliferative diseases. Three patients had EBV reactivation at higher levels of 104 IU/mL, which only occurred after two courses of alemtuzumab were administered. EBV reactivation subsided spontaneously in four cases. One patient developed EBV-positive Hodgkin lymphoma, but he had also received previously another potent T-cell suppressing drug fludarabine.ConclusionValganciclovir suppressed EBV reactivation during alemtuzumab therapy. It might be a useful prophylaxis in immunocompromized patient populations at high risk of EBV reactivation.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Clinical Virology - Volume 59, Issue 4, April 2014, Pages 255–258
نویسندگان
, , , , , , ,